12:00 AM
Mar 25, 2013
 |  BC Week In Review  |  Company News  |  Other News

Hyglos, Lonza diagnostic news

Hyglos gained rights to use recombinant factor C technology protected by Lonza's patents to produce Hyglos' endotoxin products. The deal is part of a settlement agreement dismissing a 2012...

Read the full 124 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >